The present disclosure provides a ribonucleic acid production technology. More specifically, the present disclosure provides Escherichia coli in which one or more RNA producing plasmid improvement-related (RPPI) genes are disrupted. In detail, the RPPI genes, when being disrupted, increase an mRNA synthesis evaluation value. The present disclosure also provides: a microorganism such as a microbe for mRNA production; production of a plasmid for mRNA production by using the microorganism; a plasmid produced thereby; and the like.
The present disclosure provides a method for producing a microbial strain exhibiting a desired property, such as high-throughput productivity and a property to reduce by-products, by activating a gene group. More specifically, in one aspect, the present disclosure provides a method for producing a strain having a desired property, the method comprising: (1) a step for providing a plurality of constructs including gene clusters each containing a plurality of genes, wherein promoters are arranged in a monocistronic configuration; (2) a step for preparing a combinatorial library of promoters in the constructs to introduce the promoters into a target host cell; and (3) a step for selecting a strain having a desired property in the host cell.
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymesProcédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p. ex. des bactéries ou des cellules animalesBibliothèques contenues ou présentées dans des vecteurs, p. ex. des plasmidesBibliothèques contenant uniquement des micro-organismes ou des vecteurs
3.
PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS
The present disclosure pertains to production of a virus vector plasmid in Bacillus subtilis. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced does not have be a plasmid.
The present disclosure provides a Rep and ITR-containing plasmid DNA or DNA/cationic substance complex having a high adeno-associated virus (AAV) vector productivity. More specifically, in one exemplary aspect, the present disclosure provides a nucleic acid, etc., the nucleic acid containing a Rep gene derived from an AAV of a first serotype and an inverted terminal repeat (ITR) sequence derived from an AAV of a second serotype different from the first serotype and having a ΔG value ranging from -65 to -95 kcal/mol.
C12N 15/35 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
The present disclosure provides a virus-derived gene that can be used for producing a new virus-derived construct. In more detail, the virus-derived gene according to the present disclosure includes a combination between an adenovirus-derived gene and a herpesvirus-derived gene. In one embodiment, the herpesvirus-derived gene is a gene involved in gene replication. In one embodiment, the herpesvirus-derived gene encodes a protein selected from helicase, primase, ssDNA binding proteins (DBPs), DNA polymerase, and DNA replication proteins. In one embodiment, the herpesvirus-derived gene encodes a protein selected from ssDNA binding proteins (DBPs) and DNA polymerase. In one embodiment, the herpesvirus-derived gene includes a gene selected from UL44, UL54, and UL57.
The present disclosure provides a nucleic acid construct that can control protein expression. Specifically, the present disclosure provides a nucleic acid construct including a 5' untranslated region (UTR) and a 3' UTR that are at least partially complementary to one another, wherein when at least one UTR includes a non-complementary section and a complementary section with regard to the other UTR and the length of each non-complementary section is one base, the complementarity percentage of the 3' UTR to the 5' UTR is greater than 75%.
The present disclosure provides expression control for the Rep gene by expression control of a helper gene. One aspect of the present disclosure provides a method for controlling the expression of the Rep gene that includes a step for controlling the expression of a helper gene. In one embodiment, the helper gene includes a gene selected from among adenovirus E1B, E2, E4, and VA. In one embodiment, the helper gene includes the adenovirus E1B gene. In one embodiment, the helper gene includes two or more helper genes related to production of a structure derived from an adeno-associated virus (AAV), and, as necessary, the helper gene can be selected from among E1A, E1B, E2, E4, and VA. In one embodiment, the helper gene includes a helper gene selected from among E1A and E1B and a helper gene selected from among E2, E4, and VA.
The present disclosure provides the production of a plasmid for a virus-derived structure. In one aspect, the present disclosure provides a plasmid that codes for at least some elements of a virus-derived structure. In one embodiment, the present disclosure provides a plasmid that is operably linked to and includes at least part of a nucleic acid sequence which is necessary to configure a virus-derived composition. In the one embodiment, the nucleic acid sequence which is necessary to configure the virus-derived composition includes (A) a nucleic acid sequence that includes a terminal repeating sequence, (B) a nucleic acid sequence that codes for a packaging factor, (C) a nucleic acid sequence that codes for a structural protein, and (D) a nucleic acid sequence that codes for a functional auxiliary factor.
In one aspect, the present disclosure provides a method for producing various virus-derived construct plasmids from starting plasmids (for example, the virus-derived construct plasmids of the present disclosure). In one embodiment, the method for producing virus-derived construct plasmids according to the present disclosure includes: a step for preparing a set of starting plasmids containing at least a portion of a nucleic acid sequence necessary for forming a virus-derived construct, the set of starting plasmids including a set of corresponding alternative unit nucleic acids, and the set of corresponding alternative unit nucleic acids including at least one set of corresponding alternative unit nucleic acids that contain a different nucleic acid sequence; a step for treating the set of starting plasmids with a restriction enzyme and preparing a mixed solution containing cleaved alternative unit nucleic acid fragments; a step for ligating the cleaved alternative unit nucleic acid fragments to form an integrated nucleic acid; and a step for causing the integrated nucleic acid to contact a transformed organism and thereby forming virus-derived construct plasmids.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/37 - Papovaviridae, p. ex. virus du papillome, virus du polyome, SV 40
C12N 15/48 - Rétroviridae, p. ex. virus de la leucémie bovine, virus de la leucémie féline
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis
technology; technical advisory services relating to DNA
synthesis technology; research and development relating to
production and analysis of virus vector; technological
advisory services relating to production and analysis of
virus vector; research and development relating to
production and analysis of mRNA; technological advisory
services relating to production and analysis of mRNA;
research and development relating to gene therapy; technical
advisory services relating to gene therapy research;
technological advisory services relating to productization
of gene therapy products; research and development in the
fields of bacteriology, cytology, antibody technology,
chemistry, immunology, and gene expression systems;
scientific research in the fields of genetics and genetic
engineering; DNA screening for scientific research purposes;
research and development, and technical advisory services
relating thereto in the fields of protein, antibody,
vaccine, virus, virus vector, mRNA, microorganisms, and
cells; structural and functional analysis of the genome with
genome synthesis technology; DNA screening for scientific
research purposes with genome synthesis technology; research
and development relating to genome synthesis technology;
technical advisory services relating to genome synthesis
technology; research and development, and technical advisory
services relating thereto in the fields of protein, vaccine,
virus, virus vector, mRNA, antibody, microorganisms, and
cells, all with genome synthesis technology; research and
development in the fields of bacteriology, cytology,
antibody technology, chemistry, immunology, and gene
expression systems, all with genome synthesis technology;
scientific research in the fields of genetics and genetic
engineering with genome synthesis technology; testing,
inspection, and research of pharmaceuticals, gene therapy
products, regenerative medical products, cosmetics or
foodstuffs, all with genome synthesis technology;
development of pharmaceuticals, gene therapy products,
regenerative medical products, cosmetics or foodstuffs, all
with genome synthesis technology; technical advisory
services relating to development of pharmaceuticals, gene
therapy products, regenerative medical products, cosmetics
or foodstuffs, all with genome synthesis technology; quality
testing, inspection, and research relating to medical
treatment or medical technology with genome synthesis
technology; testing and research relating to genome or gene
to which genome synthesis technology is applied; research
and development for the pharmaceutical industry and
biotechnology industry with genome synthesis technology;
research and development relating to biotechnology for
others; research and development relating to genome
synthesis technology for others; research and development
relating to production and analysis of virus vector for
others; research and development relating to gene therapy
products for others; biotechnology research; research and
development in the fields of genomics and biotechnology;
technical advisory services in the fields of genomics and
biotechnology; structural and functional analysis of
genomes; quality testing, inspection, and research in the
fields of agriculture, livestock breeding or fisheries;
development of pharmaceutical preparations and medicines;
product development for others; research and development of
new products for others; development of new technology for
others in the fields of genomics and biotechnology; research
and development of genome synthesis technology for others;
research and development of new products for others with DNA
synthesis technology; research and development in the field
of gene expression systems; research and development in the
fields of microorganisms and cells; research and development
of microorganisms for others; research and development of
microorganisms which produce useful substances for others;
bacteriological research; biological research.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis technology; technical advisory services relating to DNA synthesis technology; research and development relating to production and analysis of virus vector; technological advisory services relating to production and analysis of virus vector; research and development relating to production and analysis of mRNA; technological advisory services relating to production and analysis of mRNA; research and development relating to gene therapy; technical advisory services relating to gene therapy research; technological advisory services relating to productization of gene therapy products; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, and technical advisory services relating thereto in the fields of protein, antibody, vaccine, virus, virus vector, mRNA, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services relating to genome synthesis technology; research and development, and technical advisory services relating thereto in the fields of protein, vaccine, virus, virus vector, mRNA, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection, and research of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, gene therapy products, regenerative medical products, cosmetics or foodstuffs, all with genome synthesis technology; quality testing, inspection, and research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; research and development relating to production and analysis of virus vector for others; research and development relating to gene therapy products for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; quality testing, inspection, and research in the fields of agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; research and development in the field of gene expression systems; research and development in the fields of microorganisms and cells; research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; bacteriological research; biological research
12.
PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS
The present disclosure pertains to production of a virus vector plasmid in Bacillus subtilis. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora pour Bacillus
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
13.
PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS
The present disclosure pertains to production of a virus vector plasmid in Bacillus subtilis. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora pour Bacillus
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
The present disclosure pertains to production of a virus vector plasmid. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.
C12N 15/35 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora pour Bacillus
The present disclosure pertains to production of a virus vector plasmid. According to one aspect, the present disclosure provides a method for producing a virus vector plasmid having a sequence to be replicated in Bacillus subtilis. The method includes a step for forming a plasmid in a host cell by introducing, into the host cell, a nucleic acid that has a sequence to be replicated in Bacillus subtilis and that includes a nucleic acid sequence for producing a virus vector. In one embodiment, Bacillus subtilis could have the ability to form a plasmid from a nucleic acid acquired from outside, and therefore, in this method, the nucleic acid introduced dose not have be a plasmid.
C12N 15/35 - Parvoviridae, p. ex. virus de l'aleucémie féline, parvovirus humain
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora pour Bacillus
16.
Method for preparing DNA unit composition, and method for creating concatenated DNA
Provided are: a method for preparing a DNA unit composition in which the mol number of a plurality of DNA units is more uniform, and a method for creating concatenated DNA. The method for preparing a DNA unit composition has: a step for preparing solutions which contain a plurality of DNA units to which an added sequence is linked, and preparing a solution for each type of DNA unit and a step for, after preparing each of the solutions, measuring the concentration of the DNA unit in each of the solutions in a state where the added sequence is linked to the DNA unit, and on the basis of the results thereof, fractionating each of the solutions and making the mol number of the DNA unit in each of the solutions closer to being identical to one another.
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis
technology; technical advisory services and information
technology services relating to DNA synthesis technology;
research and development in the fields of bacteriology,
cytology, antibody technology, chemistry, immunology, and
gene expression systems; scientific research in the fields
of genetics and genetic engineering; DNA screening for
scientific research purposes; research and development,
quality control, and technical advisory services relating
thereto in the fields of protein, antibody, microorganisms,
and cells; structural and functional analysis of the genome
with genome synthesis technology; DNA screening for
scientific research purposes with genome synthesis
technology; research and development relating to genome
synthesis technology; technical advisory services and
information technology services relating to genome synthesis
technology; research and development, quality control, and
technical advisory services relating thereto in the fields
of protein, antibody, microorganisms, and cells, all with
genome synthesis technology; research and development in the
fields of bacteriology, cytology, antibody technology,
chemistry, immunology, and gene expression systems, all with
genome synthesis technology; scientific research in the
fields of genetics and genetic engineering with genome
synthesis technology; testing, inspection or research of
pharmaceuticals, cosmetics or foodstuffs, all with genome
synthesis technology; development of pharmaceuticals,
cosmetics or foodstuffs, all with genome synthesis
technology; technical advisory services relating to
development of pharmaceuticals, cosmetics or foodstuffs, all
with genome synthesis technology; information technology
services relating to development of pharmaceuticals,
cosmetics or foodstuffs, all with genome synthesis
technology; testing, inspection or research relating to
medical treatment or medical technology with genome
synthesis technology; information technology services for
testing, inspection or research relating to medical
treatment or medical technology with genome synthesis
technology; testing or research relating to genome or gene
to which genome synthesis technology is applied; research
and development for the pharmaceutical industry and
biotechnology industry with genome synthesis technology;
research and development relating to biotechnology for
others; research and development relating to genome
synthesis technology for others; biotechnology research;
research and development in the fields of genomics and
biotechnology; technical advisory services in the fields of
genomics and biotechnology; structural and functional
analysis of genomes; testing, inspection or research on
agriculture, livestock breeding or fisheries; development of
pharmaceutical preparations and medicines; product
development for others; research and development of new
products for others; development of new technology for
others in the fields of genomics and biotechnology; research
and development of genome synthesis technology for others;
research and development of new products for others with DNA
synthesis technology; DNA synthesis services for others;
research and development services in the field of gene
expression systems; research and development services in the
fields of microorganisms and cells; DNA sequence design
services; research and development of microorganisms for
others; research and development of microorganisms which
produce useful substances for others; technical research;
bacteriological research; biological research.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis
technology; technical advisory services and information
technology services relating to DNA synthesis technology;
research and development in the fields of bacteriology,
cytology, antibody technology, chemistry, immunology, and
gene expression systems; scientific research in the fields
of genetics and genetic engineering; DNA screening for
scientific research purposes; research and development,
quality control, and technical advisory services relating
thereto in the fields of protein, antibody, microorganisms,
and cells; structural and functional analysis of the genome
with genome synthesis technology; DNA screening for
scientific research purposes with genome synthesis
technology; research and development relating to genome
synthesis technology; technical advisory services and
information technology services relating to genome synthesis
technology; research and development, quality control, and
technical advisory services relating thereto in the fields
of protein, antibody, microorganisms, and cells, all with
genome synthesis technology; research and development in the
fields of bacteriology, cytology, antibody technology,
chemistry, immunology, and gene expression systems, all with
genome synthesis technology; scientific research in the
fields of genetics and genetic engineering with genome
synthesis technology; testing, inspection or research of
pharmaceuticals, cosmetics or foodstuffs, all with genome
synthesis technology; development of pharmaceuticals,
cosmetics or foodstuffs, all with genome synthesis
technology; technical advisory services relating to
development of pharmaceuticals, cosmetics or foodstuffs, all
with genome synthesis technology; information technology
services relating to development of pharmaceuticals,
cosmetics or foodstuffs, all with genome synthesis
technology; testing, inspection or research relating to
medical treatment or medical technology with genome
synthesis technology; information technology services for
testing, inspection or research relating to medical
treatment or medical technology with genome synthesis
technology; testing or research relating to genome or gene
to which genome synthesis technology is applied; research
and development for the pharmaceutical industry and
biotechnology industry with genome synthesis technology;
research and development relating to biotechnology for
others; research and development relating to genome
synthesis technology for others; biotechnology research;
research and development in the fields of genomics and
biotechnology; technical advisory services in the fields of
genomics and biotechnology; structural and functional
analysis of genomes; testing, inspection or research on
agriculture, livestock breeding or fisheries; development of
pharmaceutical preparations and medicines; product
development for others; research and development of new
products for others; development of new technology for
others in the fields of genomics and biotechnology; research
and development of genome synthesis technology for others;
research and development of new products for others with DNA
synthesis technology; DNA synthesis services for others;
research and development services in the field of gene
expression systems; research and development services in the
fields of microorganisms and cells; DNA sequence design
services; research and development of microorganisms for
others; research and development of microorganisms which
produce useful substances for others; technical research;
bacteriological research; biological research.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis
technology; technical advisory services and information
technology services relating to DNA synthesis technology;
research and development in the fields of bacteriology,
cytology, antibody technology, chemistry, immunology, and
gene expression systems; scientific research in the fields
of genetics and genetic engineering; DNA screening for
scientific research purposes; research and development,
quality control, and technical advisory services relating
thereto in the fields of protein, antibody, microorganisms,
and cells; structural and functional analysis of the genome
with genome synthesis technology; DNA screening for
scientific research purposes with genome synthesis
technology; research and development relating to genome
synthesis technology; technical advisory services and
information technology services relating to genome synthesis
technology; research and development, quality control, and
technical advisory services relating thereto in the fields
of protein, antibody, microorganisms, and cells, all with
genome synthesis technology; research and development in the
fields of bacteriology, cytology, antibody technology,
chemistry, immunology, and gene expression systems, all with
genome synthesis technology; scientific research in the
fields of genetics and genetic engineering with genome
synthesis technology; testing, inspection or research of
pharmaceuticals, cosmetics or foodstuffs, all with genome
synthesis technology; development of pharmaceuticals,
cosmetics or foodstuffs, all with genome synthesis
technology; technical advisory services relating to
development of pharmaceuticals, cosmetics or foodstuffs, all
with genome synthesis technology; information technology
services relating to development of pharmaceuticals,
cosmetics or foodstuffs, all with genome synthesis
technology; testing, inspection or research relating to
medical treatment or medical technology with genome
synthesis technology; information technology services for
testing, inspection or research relating to medical
treatment or medical technology with genome synthesis
technology; testing or research relating to genome or gene
to which genome synthesis technology is applied; research
and development for the pharmaceutical industry and
biotechnology industry with genome synthesis technology;
research and development relating to biotechnology for
others; research and development relating to genome
synthesis technology for others; biotechnology research;
research and development in the fields of genomics and
biotechnology; technical advisory services in the fields of
genomics and biotechnology; structural and functional
analysis of genomes; testing, inspection or research on
agriculture, livestock breeding or fisheries; development of
pharmaceutical preparations and medicines; product
development for others; research and development of new
products for others; development of new technology for
others in the fields of genomics and biotechnology; research
and development of genome synthesis technology for others;
research and development of new products for others with DNA
synthesis technology; DNA synthesis services for others;
research and development services in the field of gene
expression systems; research and development services in the
fields of microorganisms and cells; DNA sequence design
services; research and development of microorganisms for
others; research and development of microorganisms which
produce useful substances for others; technical research;
bacteriological research; biological research.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology [ services ] relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; technical advisory services and * providing * information technology [ services ]relating to genome synthesis technology; research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; * providing * information technology [ services ] relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing or research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; [ DNA sequence design services; ] research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development relating to DNA synthesis technology; technical advisory services and * providing * information technology consulting services relating to DNA synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the fields of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells; structural and functional analysis of the genome with genome synthesis technology; DNA screening for scientific research purposes with genome synthesis technology; research and development relating to genome synthesis technology; * providing * technical advisory services and information technology consulting services relating to genome synthesis technology; research and development, quality control for others, and technical advisory services relating thereto in the fields of protein, antibody, microorganisms, and cells, all with genome synthesis technology; research and development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems, all with genome synthesis technology; scientific research in the fields of genetics and genetic engineering with genome synthesis technology; testing, inspection and research of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; * providing * technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; information technology services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome synthesis technology; testing, inspection and research relating to medical treatment or medical technology with genome synthesis technology; * providing * information technology consulting services for testing, inspection or research relating to medical treatment or medical technology with genome synthesis technology; testing and research relating to genome or gene to which genome synthesis technology is applied; research and development for the pharmaceutical industry and biotechnology industry with genome synthesis technology; research and development relating to biotechnology for others; research and development relating to genome synthesis technology for others; biotechnology research; research and development in the fields of genomics and biotechnology; technical advisory services in the fields of genomics and biotechnology; structural and functional analysis of genomes; testing, inspection or research on agriculture, livestock breeding or fisheries; development of pharmaceutical preparations and medicines; product development for others; research and development of new products for others; development of new technology for others in the fields of genomics and biotechnology; research and development of genome synthesis technology for others; research and development of new products for others with DNA synthesis technology; DNA synthesis services for others for scientific research purposes; research and development services in the field of gene expression systems; research and development services in the fields of microorganisms and cells; [ DNA sequence design services for scientific research purposes; ] research and development of microorganisms for others; research and development of microorganisms which produce useful substances for others; technical research in the field of microorganisms; bacteriological research; biological research
22.
Method for preparing DNA unit composition, and method for creating concatenated DNA
Provided are: a method for preparing a DNA unit composition in which the mol number of a plurality of DNA units is more uniform, and a method for creating concatenated DNA. The method for preparing a DNA unit composition has: a step for preparing solutions which contain a plurality of DNA units to which an added sequence is linked, and preparing a solution for each type of DNA unit; and a step for, after preparing each of the solutions, measuring the concentration of the DNA unit in each of the solutions in a state where the added sequence is linked to the DNA unit, and on the basis of the results thereof, fractionating each of the solutions and making the mol number of the DNA unit in each of the solutions closer to being identical to one another.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
